Literatur
- 1
Targan S R, Hanauer S B, van Deventer S J. et al .
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha
for Crohn’s disease. Crohn’s Disease cA2 Study Group.
N Engl J Med.
1997;
337
1029-1035
- 2
Hanauer S B, Feagan B G, Lichtenstein G R. et al .
Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial.
Lancet.
2002;
359
1541-1549
- 3
Present D H, Rutgeerts P, Targan S. et al .
Infliximab for the treatment of fistulas in patients with Crohn’s disease.
N Engl J Med.
1999;
340
1398-1405
- 4
Sands B E, Anderson F H, Bernstein C N. et al .
Infliximab maintenance therapy for fistulizing Crohn’s disease.
N Engl J Med.
2004;
350
876-885
- 5
Baert F, Noman M, Vermeire S. et al .
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn’s Disease.
N Engl J Med.
2003;
348
601-608
- 6
Papadakis K A, Shayne O A, Vasiliauskas E A. et al .
Safety and efficacy of adalimumab (D2E7) in Crohn’s disease patients with an attenuated
response to Infliximab.
Am J Gastroenterol.
2005;
100
75-79
- 7
Youdim A, Vasiliauskas E A, Targan S R. et al .
A pilot study of adalimumab in infliximab-allergic patients.
Inflamm Bowel Dis.
2004;
10
333-338
- 8
Sandborn W J, Hanauer S, Loftus E V. et al .
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects
with prior loss of response or intolerance to infliximab in Crohn’s diseease.
Am J Gastroenterol.
2004;
99
1984-1989
- 9
Shen C, Asshe G V, Colpaert S. et al .
Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab
and etanercept.
Aliment Pharmacol Ther.
2005;
21
251-258
Prof. Dr. P. R. Galle
I. Med. Klinik und Poliklinik · Johannes Gutenberg-Universität Mainz
Langenbeckstraße 1 · 55131 Mainz
Email: galle@mail.uni-mainz.de
